ALS Drug Development Summit 2026

June 2-4, 2026
Boston, Massachusetts

The ALS Drug Development Summit, taking place June 2-4, 2026, in Boston, MA, brings together biotech, pharmaceutical, and academic leaders focused on advancing therapies for ALS and frontotemporal dementia (FTD). The meeting spans the full development continuum, with dedicated focus on clinical strategy, regulatory pathways, and translational progress in neurodegenerative disease.

For sponsors advancing ALS and FTD therapies, the conference highlights many of the practical challenges shaping modern neurodegenerative drug development, including biomarker integration, adaptive and platform trial designs, digital endpoints, patient stratification, endpoint selection, and alignment with evolving regulatory expectations.

These themes closely parallel the operational realities of ALS clinical trials, where study design, site strategy, patient experience, caregiver coordination, and emerging biomarker and endpoint strategies can all influence execution.

PRC Clinical supports ALS and neurodegenerative programs with hands-on clinical operations teams experienced in complex study designs, including gene therapy, stem cell therapies, advanced endpoint strategies, and complex neurosurgical delivery. Across early-phase through later-stage development, PRC focuses on site readiness, rater training, and managing patient and caregiver burden across specialized studies.

For up-to-date conference information, please visit the conference website linked below. To connect with the PRC Clinical team, fill out the form below.

View the Conference Website